In 17 patients with lipodystrophy, tirzepatide significantly reduced HbA1c by 1.1%, triglycerides by 65 mg/dL, and daily insulin requirements by 109 units after about 9 months of treatment.
109 units/day reduction in insulinLipodystrophy patients — who often require hundreds of units of insulin daily — reduced their insulin needs by a median of 109 units/day on tirzepatide, with one patient reducing by 315 units.
What the researchers found
After a median 8.7 months of tirzepatide treatment in 17 lipodystrophy patients (14 with FPLD): BMI decreased by median 1.7 kg/m² (p=0.008), HbA1c decreased by median 1.1% (range -6.3% to -0.1%, p<0.001), triglycerides decreased by median 65 mg/dL (with one patient dropping 3,820 mg/dL; p=0.003), and total daily insulin requirements decreased by median 109 units (range -315 to 0 units, p=0.002). Three additional patients with rarer lipodystrophy forms (atypical PL, acquired GL) also showed robust responses. Side effects were limited to benign gastrointestinal symptoms.
Why it matters
Lipodystrophy patients face severe metabolic complications with very limited treatment options — the only approved therapy (metreleptin) has significant limitations. Many patients require hundreds of units of insulin daily and still have dangerously high blood sugar and triglycerides. Finding that tirzepatide dramatically improves these parameters, including reducing insulin needs by over 100 units daily, could transform care for this rare disease population.
How the study worked
Observational cohort study of lipodystrophy patients receiving tirzepatide as part of clinical care, tracked within ongoing natural history studies. Seventeen patients were followed for a median of 8.7 months. Outcomes included BMI, HbA1c, triglycerides, and total daily insulin requirements. Statistical significance was assessed using non-parametric tests given the small sample size. Three additional rare lipodystrophy cases were described.
What this study cannot tell us
Very small observational cohort (17 patients) without a control group — the gold standard for treatment evaluation. Results could be influenced by concurrent medications, dietary changes, or natural disease fluctuation. The wide ranges in outcomes (e.g., triglyceride reduction from -3,820 to +43 mg/dL) indicate highly variable individual responses. Published in Diabetes Care as a report rather than a randomized trial. The rare nature of lipodystrophy inherently limits sample sizes, but this means the evidence remains preliminary.
How to read the evidence
This is a small observational cohort (n=17) without randomization or a control group, representing the lowest tier of clinical evidence. However, for a rare disease affecting perhaps a few thousand people worldwide, this is a meaningful contribution. The statistically significant improvements across multiple endpoints increase confidence despite the small sample.
When this study was published
Published in 2025 in Diabetes Care, this is among the first reports of tirzepatide use in lipodystrophy and could guide future clinical trials in this rare disease.
The bigger picture
GLP-1 and dual-agonist drugs keep expanding into rare diseases beyond obesity and diabetes. Lipodystrophy is a particularly challenging condition because the underlying problem — lack of fat tissue — is opposite to obesity. The fact that tirzepatide still works in this opposite metabolic context suggests its benefits extend beyond simple fat reduction to fundamental improvements in metabolic signaling and glucose handling. This could open pathways for other rare metabolic diseases.
Questions still open
- What mechanism allows tirzepatide to improve metabolic parameters in lipodystrophy, where the fundamental problem is inadequate fat tissue rather than excess fat?
- How does tirzepatide compare to metreleptin (the only approved lipodystrophy treatment) in head-to-head comparison?
- Would combining tirzepatide with metreleptin provide additive benefits for the most severely affected patients?
Common questions
What is lipodystrophy and why is tirzepatide interesting for it?
Isn't tirzepatide a weight loss drug — how does it help people who lack fat?
Read the original research
Metabolic Improvements With Tirzepatide in Lipodystrophy: A Novel Option?
Diabetes care, 48(5), 756-762
Citation
Meral, Rasimcan; Celik Guler, Merve; Kaba, Diarratou; Prativadi, Jeevitha; Frontera, Eric D; Foss-Freitas, Maria Cristina; Nachawi, Noura; Broome, David T; Lightbourne, Marissa; Brown, Rebecca J; Taylor, Simeon I; Oral, Elif A. (2025). Metabolic Improvements With Tirzepatide in Lipodystrophy: A Novel Option?. Diabetes care, 48(5), 756-762. https://doi.org/10.2337/dc24-2408